| HOME >> BIOLOGY >> TECHNOLOGY |
- Conference Call Today at 5:00 p.m. EDT -
VALENCIA, Calif., Aug. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2008.
For the second quarter of 2008, total operating expenses were $80.9 million, compared to $75.4 million for the second quarter of 2007. This increase was primarily attributable to increased research and development (R&D) expenses which totaled $67.6 million for this quarter compared to $61.5 million for the same quarter in 2007. The increase in research and development expenses for the three months ended June 30, 2008 as compared to the same period in the prior year was primarily due to increases in manufacturing costs, clinical trial costs, and stock-based compensation expense. General and administrative (G&A) expenses decreased by $0.6 million to $13.3 million for the second quarter of 2008 compared to the second quarter of 2007. The decrease in general and administrative expenses for the three months ended June 30, 2008 as compared to the same period in the prior year was primarily due to lower professional service fees, partially offset by increases in stock-based compensation expense and salary related expenses.
For the first six months of 2008, operating expenses totaled $154.9
million, compared to $152.7 million in the first half of 2007. R&D expenses
for the first six months were $126.0 million, compared to $125.3 million in
2007. The increase in R&D expenses for the first six months was primarily
due to increases in stock-based compensation expense and manufacturing
costs, partially offset by lower clinical trial costs. G&A expenses
increased by $1.5 million to $28.9 million for the first half
'/>"/>
| SOURCE MannKind Corporation Copyright©2008 PR Newswire. All rights reserved |